Abstract:Fragile X syndrome (FXS) is caused by silencing of the FMR1 gene, which encodes a protein with a critical role in synaptic plasticity. The molecular abnormality underlying FMR1 silencing, CGG repeat expansion, is well characterized; however, delineation of the pathway from DNA to RNA to protein using biosamples from well characterized patients with FXS is limited. Since FXS is a common and prototypical genetic disorder associated with intellectual disability (ID) and autism spectrum disorder (ASD), a comprehensive assessment of the FMR1 DNA-RNA-protein pathway and its correlations with the neurobehavioral phenotype is a priority. We applied nine sensitive and quantitative assays evaluating FMR1 DNA, RNA, and FMRP parameters to a reference set of cell lines representing the range of FMR1 expansions. We then used the most informative of these assays on blood and buccal specimens from cohorts of patients with different FMR1 expansions, with emphasis on those with FXS (N = 42 total, N = 31 with FMRP measurements). The group with FMRP data was also evaluated comprehensively in terms of its neurobehavioral profile, which allowed molecular–neurobehavioral correlations. FMR1 CGG repeat expansions, methylation levels, and FMRP levels, in both cell lines and blood samples, were consistent with findings of previous FMR1 genomic and protein studies. They also demonstrated a high level of agreement between blood and buccal specimens. These assays further corroborated previous reports of the relatively high prevalence of methylation mosaicism (slightly over 50% of the samples). Molecular-neurobehavioral correlations confirmed the inverse relationship between overall severity of the FXS phenotype and decrease in FMRP levels (N = 26 males, mean 4.2 ± 3.3 pg FMRP/ng genomic DNA). Other intriguing findings included a significant relationship between the diagnosis of FXS with ASD and two-fold lower levels of FMRP (mean 2.8 ± 1.3 pg FMRP/ng genomic DNA, p = 0.04), in particular observed in younger age- and IQ-adjusted males (mean age 6.9 ± 0.9 years with mean 3.2 ± 1.2 pg FMRP/ng genomic DNA, 57% with severe ASD), compared to FXS without ASD. Those with severe ID had even lower FMRP levels independent of ASD status in the male-only subset. The results underscore the link between FMR1 expansion, gene methylation, and FMRP deficit. The association between FMRP deficiency and overall severity of the neurobehavioral phenotype invites follow up studies in larger patient cohorts. They would be valuable to confirm and potentially extend our initial findings of the relationship between ASD and other neurobehavioral features and the magnitude of FMRP deficit. Molecular profiling of individuals with FXS may have important implications in research and clinical practice.

Pain and gain of predictive genetic testing: Particular case of fragile X syndrome

Prenatal diagnosis and genetic counseling of fragile X syndrome in four pedigrees by using high-resolution multiplex polymerase chain reaction

Parent perspectives following newborn screening resulting in diagnoses of fragile X syndrome or fragile X premutation

Genetic Diagnosis and Prenatal Genetic Diagnosis of Fragile X Syndrome

Preimplantation genetic diagnosis for fragile X syndrome: is there increased transmission of abnormal FMR1 alleles among female heterozygotes?

[Familial fragile X syndrome: A pedigree analysis]

An escalating continuum of learning and attention difficulties from premutation to full mutation in female carriers of FMR1 expansion

Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes

Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome

Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population.

Fragile X syndrome in children with learning difficulties and the diagnostic dilemma

Analysis and Prenatal Diagnosis of FMR1 Gene Mutations among Patients with Unexplained Mental Retardation

Psychological status in female carriers of premutation FMR1 allele showing a complex relationship with the size of CGG expansion

A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Development of Genetic Testing for Fragile X Syndrome and Associated Disorders, and Estimates of the Prevalence of FMR1 Expansion Mutations

New Targeted Treatments for Fragile X Syndrome

Duan Tolerance for Point Mutation Gene in Chinese Pediatric Population of Fragile X Suspects : Low FMR 1 Mutational Analyses of the

Development of Chinese Genetic Reference Panel for Fragile X Syndrome and Its Application to the Screen of 10,000 Chinese Pregnant Women and Women Planning Pregnancy

Analysis of CGG Repeat Instability in Germline Cells from Two Male Fetuses Affected with Fragile X Syndrome

The Spectrum of Neurological and White Matter Changes and Premutation Status Categories of Older Male Carriers of the FMR1 Alleles Are Linked to Genetic (CGG and FMR1 mRNA) and Cellular Stress (AMPK) Markers